Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer

Debra L. Richardson, Shelly M. Seward, Kathleen N. Moore

Research output: Contribution to journalArticle

Abstract

Antibody drug conjugates are novel mechanisms for delivering chemotherapy. They vary based on the targeted antigen, conjugated cytotoxic, and the type of linker used. These differences determine what cells are targeted. There are 2 antibody drug conjugates approved for use in cancer. For epithelial ovarian cancer, more than 15 antibody drug conjugates are under study. Using antibody drug conjugates in epithelial ovarian cancer makes sense. This review discusses promising trial results demonstrating efficacy. Reported toxicities include visual disturbance. There is an absence of significant hematologic toxicity. Overlapping toxicity between standard cytotoxics and antibody drug conjugates includes neuropathy and constitutional symptoms.

Original languageEnglish (US)
JournalHematology/Oncology Clinics of North America
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Antibodies
Pharmaceutical Preparations
Therapeutics
Ovarian epithelial cancer
Antigens
Drug Therapy
Neoplasms

Keywords

  • ADC
  • Antibody drug conjugates
  • Clinical trials
  • Gynecologic malignancy
  • Ovarian cancer
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. / Richardson, Debra L.; Seward, Shelly M.; Moore, Kathleen N.

In: Hematology/Oncology Clinics of North America, 01.01.2018.

Research output: Contribution to journalArticle

@article{c5e371dd11d346848e0f07d3fab05b28,
title = "Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer",
abstract = "Antibody drug conjugates are novel mechanisms for delivering chemotherapy. They vary based on the targeted antigen, conjugated cytotoxic, and the type of linker used. These differences determine what cells are targeted. There are 2 antibody drug conjugates approved for use in cancer. For epithelial ovarian cancer, more than 15 antibody drug conjugates are under study. Using antibody drug conjugates in epithelial ovarian cancer makes sense. This review discusses promising trial results demonstrating efficacy. Reported toxicities include visual disturbance. There is an absence of significant hematologic toxicity. Overlapping toxicity between standard cytotoxics and antibody drug conjugates includes neuropathy and constitutional symptoms.",
keywords = "ADC, Antibody drug conjugates, Clinical trials, Gynecologic malignancy, Ovarian cancer, Toxicity",
author = "Richardson, {Debra L.} and Seward, {Shelly M.} and Moore, {Kathleen N.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.hoc.2018.07.014",
language = "English (US)",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer

AU - Richardson, Debra L.

AU - Seward, Shelly M.

AU - Moore, Kathleen N.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Antibody drug conjugates are novel mechanisms for delivering chemotherapy. They vary based on the targeted antigen, conjugated cytotoxic, and the type of linker used. These differences determine what cells are targeted. There are 2 antibody drug conjugates approved for use in cancer. For epithelial ovarian cancer, more than 15 antibody drug conjugates are under study. Using antibody drug conjugates in epithelial ovarian cancer makes sense. This review discusses promising trial results demonstrating efficacy. Reported toxicities include visual disturbance. There is an absence of significant hematologic toxicity. Overlapping toxicity between standard cytotoxics and antibody drug conjugates includes neuropathy and constitutional symptoms.

AB - Antibody drug conjugates are novel mechanisms for delivering chemotherapy. They vary based on the targeted antigen, conjugated cytotoxic, and the type of linker used. These differences determine what cells are targeted. There are 2 antibody drug conjugates approved for use in cancer. For epithelial ovarian cancer, more than 15 antibody drug conjugates are under study. Using antibody drug conjugates in epithelial ovarian cancer makes sense. This review discusses promising trial results demonstrating efficacy. Reported toxicities include visual disturbance. There is an absence of significant hematologic toxicity. Overlapping toxicity between standard cytotoxics and antibody drug conjugates includes neuropathy and constitutional symptoms.

KW - ADC

KW - Antibody drug conjugates

KW - Clinical trials

KW - Gynecologic malignancy

KW - Ovarian cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85054071486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054071486&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2018.07.014

DO - 10.1016/j.hoc.2018.07.014

M3 - Article

C2 - 30390760

AN - SCOPUS:85054071486

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

ER -